Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18

Roche announces FDA grants accelerated approval for Venclexta combo

Roche (RHHBY) announced that the U.S. Food and Drug Administration has granted accelerated approval to Venclexta, in combination with a hypomethylating agent, or low-dose cytarabine, for the treatment of people with newly-diagnosed acute myeloid leukaemia, or AML, who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. This approval of Venclexta is based on surrogate endpoints that are reasonably likely to predict clinical benefit, including CR and CRh. Continued approval for this indication may be contingent upon verification and description of clinical benefit observed in confirmatory trials. Venclexta is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie (ABBV) and Genentech, a member of the Roche Group, in the U.S. and commercialized by AbbVie outside of the U.S.

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
11/13/18
LEER
11/13/18
INITIATION
Target $18
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started AC Immune with an Outperform and $18 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding AC Immune, Goodman notes that it has a diversified pipeline of drug candidates and diagnostics for Alzheimer's disease led by a late stage antibody with crenezumab, and has strong partners with Roche (RHHBY) for crenezumab, Johnson & Johnson (JNJ) for Anti-Tau vaccine, Biogen (BIIB) for alphasynuclein-PET tracer diagnostic, and Piramal for TauPET tracer diagnostic.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/19/18
GSCO
11/19/18
DOWNGRADE
GSCO
Buy
Roche downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis removed Roche from her firm's Conviction List but keeps a Buy rating on the shares. A number of "sentiment overhangs" in the near-term, namely the launch of U.S. biosimilars, combined with a lack of tangible catalysts could limit share upside, says the analyst.
ABBV AbbVie
$85.75

-2.35 (-2.67%)

10/25/18
BMOC
10/25/18
NO CHANGE
Target $192
BMOC
Outperform
Vertex price target lowered to $192 from $204 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve. The analyst adds that while the Galapagos interim data did not make competitive inroads on Vertex therapies, he is still lowering the the FY19 EPS view for the latter to $4.43 from $5.13 on slow ex-U.S. growth amid reimbursement challenges and higher operating expenses. Longer term, Kim keeps his Outperform rating on Vertex.
10/30/18
NOMU
10/30/18
NO CHANGE
Target $140
NOMU
Buy
Galapagos price target raised to $140 from $124 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Galapagos NV to $140 following last week's Q3 results and the sale of its partnered-cystic fibrosis program back to AbbVie (ABBV) for $45M upfront and $200M in milestones. The analyst views the upfront payments as upside to expectations and keeps a Buy rating on Galapagos shares.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.
11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".

TODAY'S FREE FLY STORIES

SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

, GOV

Government Properties

$7.68

-0.41 (-5.07%)

17:08
12/15/18
12/15
17:08
12/15/18
17:08
Conference/Events
Select Income REIT to host special shareholder meeting »

Special Shareholder…

SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

GOV

Government Properties

$7.68

-0.41 (-5.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

GOV

Government Properties

$7.68

-0.41 (-5.07%)

, SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

17:06
12/15/18
12/15
17:06
12/15/18
17:06
Conference/Events
Government Properties to host special shareholder meeting »

Special Shareholder…

GOV

Government Properties

$7.68

-0.41 (-5.07%)

SIR

Select Income REIT

$17.72

-0.52 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

12:37
12/15/18
12/15
12:37
12/15/18
12:37
Periodicals
U.S. stocks could rally about 10% in 2019, Barron's says »

As U.S. stocks stumble…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

, ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

12:21
12/15/18
12/15
12:21
12/15/18
12:21
Periodicals
Alphabet, Apple among top stock picks for 2019, Barron's says »

Even if investors have…

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

DDAIF

Daimler AG

$0.00

(0.00%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

BAC

Bank of America

$24.49

0.1 (0.41%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 12

    Feb

  • 03

    Mar

DDAIF

Daimler AG

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

08:26
12/15/18
12/15
08:26
12/15/18
08:26
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

F

Ford

$8.53

0.025 (0.29%)

GM

General Motors

$35.10

-0.01 (-0.03%)

HMC

Honda

$26.90

-0.33 (-1.21%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$120.06

-0.83 (-0.69%)

VLKAY

Volkswagen

$0.00

(0.00%)

TSLA

Tesla

$365.69

-11.17 (-2.96%)

LITE

Lumentum

$43.46

-0.4 (-0.91%)

OCLR

Oclaro

$8.27

(0.00%)

FNSR

Finisar

$21.74

-0.4 (-1.81%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

INFN

Infinera

$4.14

-0.095 (-2.25%)

CIEN

Ciena

$34.55

-0.35 (-1.00%)

GOOS

Canada Goose

$52.18

-2.48 (-4.54%)

FDX

FedEx

$184.08

-3.13 (-1.67%)

UPS

UPS

$98.67

-2.1 (-2.08%)

AMZN

Amazon.com

$1,592.14

-67.86 (-4.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

  • 20

    Dec

  • 07

    Jan

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/15/18
12/15
04:55
12/15/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

  • 12

    Dec

  • 12

    Dec

TEVA

Teva

$18.46

-0.56 (-2.94%)

18:34
12/14/18
12/14
18:34
12/14/18
18:34
Hot Stocks
Teva, Celltrion announce FDA approval of HERZUMA »

Celltrion and Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVG

Pretium Resources

$7.43

(0.00%)

18:11
12/14/18
12/14
18:11
12/14/18
18:11
Hot Stocks
Pretium Resources: Brucejack approved for production hike to 3,800 tonnes/day »

Pretium Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

17:52
12/14/18
12/14
17:52
12/14/18
17:52
Periodicals
FCA says four U.S. plants to have down-time in January, Detroit News says »

Fiat Chrysler said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

, CCNI

Command Center

$4.00

-0.075 (-1.84%)

17:43
12/14/18
12/14
17:43
12/14/18
17:43
Hot Stocks
Sonoma Pharmaceuticals CEO Jim Schutz resigns, Frederick Sandford succeeds »

Sonoma Pharmaceuticals…

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

CCNI

Command Center

$4.00

-0.075 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

, XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

17:38
12/14/18
12/14
17:38
12/14/18
17:38
General news
Week ending ETF scorecard: Energy, Financials lead the decline »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

IYR

DJ US Real Estate Index Fund

$80.37

-0.14 (-0.17%)

XLP

Consumer Staples Sector SPDR

$54.51

-0.97 (-1.75%)

XLY

Consumer Discretionary Sector SPDR

$102.33

-1.75 (-1.68%)

XLB

S&P Select Materials SPDR

$51.37

-0.37 (-0.72%)

XLF

Financial Select Sector

$24.25

-0.24 (-0.98%)

XLV

Health Care Select Sector SPDR

$88.99

-3.05 (-3.31%)

XLK

Technology Select Sector SPDR

$64.58

-1.6 (-2.42%)

XLI

Industrial Select Sector SPDR

$67.06

-0.95 (-1.40%)

GLD

SPDR Gold Shares

$117.10

-0.44 (-0.37%)

SLV

iShares Silver Trust

$13.69

-0.175 (-1.26%)

USO

United States Oil Fund

$10.83

-0.38 (-3.39%)

UNG

United States Natural Gas Fund

$30.78

-2.64 (-7.90%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.17

-0.365 (-0.44%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.72

-0.125 (-0.11%)

TLT

iShares 20+ Year Treasury Bond Fund

$118.47

0.38 (0.32%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.57

0.19 (0.19%)

SHY

iShares 1-3 Year Treasury Bond

$83.31

0.055 (0.07%)

IWD

iShares Russell 1000 Value

$116.15

-1.71 (-1.45%)

IWF

iShares Russell 1000 Growth

$135.70

-2.96 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEI

Ecology & Environment

$11.50

0.2 (1.77%)

17:35
12/14/18
12/14
17:35
12/14/18
17:35
Hot Stocks
Ecology & Environment receives Nasdaq noncompliance notice »

On December 13, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$8.96

-0.045 (-0.50%)

17:34
12/14/18
12/14
17:34
12/14/18
17:34
Hot Stocks
Luther Burbank announces systematic share repurchase plan »

Luther Burbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$1.33

0.01 (0.76%)

17:31
12/14/18
12/14
17:31
12/14/18
17:31
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLGT

Radiant Logistics

$4.76

-0.06 (-1.24%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on Radiant Logistics »

Radiant Logistics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$22.62

-1.39 (-5.79%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on KalVista »

KalVista files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

17:25
12/14/18
12/14
17:25
12/14/18
17:25
Hot Stocks
POTUS names Mick Mulvaney acting WH chief of staff »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$169.87

-2.585 (-1.50%)

17:20
12/14/18
12/14
17:20
12/14/18
17:20
Hot Stocks
Raytheon awarded $149.44M Navy contract for Standard Missile-2 Block IIIC »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$100.08

-2.73 (-2.66%)

17:15
12/14/18
12/14
17:15
12/14/18
17:15
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNCB

First National Community Bancorp, Inc.

$9.35

0.04 (0.43%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
First National Community Bancorp names R. Gregory Collins as new EVP »

FNCB Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.49

-0.48 (-0.96%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Textron awarded $314.29M Navy contract modification for LLTM procurement »

Textron has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Breaking Hot Stocks news story on Fluidigm »

Levin Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WTFC

Wintrust Financial

$67.41

-0.88 (-1.29%)

17:06
12/14/18
12/14
17:06
12/14/18
17:06
Hot Stocks
Wintrust Financial acquires Elektra Holding in roughly $51.9M deal »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$14.51

-0.35 (-2.36%)

17:04
12/14/18
12/14
17:04
12/14/18
17:04
Syndicate
Breaking Syndicate news story on AMC Entertainment »

AMC Entertainment files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.19

0.07 (0.07%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Equifax Canada acquires JLR Inc. »

Equifax Canada announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.